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Prostate cancer remains the most frequently diagnosed solid
tumour and is the second leading cause of cancer-related death in
men in Western countries (Nomura and Kolonel, 1991). Most
prostate cancers are treated with androgen ablation, resulting in
subjective improvement in ~ 70%. However, the response is
usually temporary and offers no realistic possibility of cure (Byrne
et al, 1996). Current data suggest that transformed prostate cells
are able to overcome normal growth restraints by producing
growth factors, such as epidermal growth factor (EGF) and
transforming growth factor a (TGF-a), which act through
autocrine and paracrine mechanisms to stimulate growth (Wilding
et al, 1989; Xie et al, 1995).
The epidermal growth factor receptor (EGFR) and two of its
multiple high affinity ligands, EGF and TGF-a, play an important
role in the development of several different human cancers
(Todaro et al, 1979; Lippman, 1993), including prostate cancer
(Ching et al, 1993). Several studies have shown that prostate
cancer cells express EGF, TGF-a and EGFR mRNA and protein
(Morris and Dodd, 1990; Ching et al, 1993; Glynne-Jones et al,
1996). Further, recent immunohistochemical and in situ hybridiza-
tion analysis showed that the levels of EGFR and TGF-a mRNA
and protein are increased in carcinoma cells compared to benign
epithelium (Ching et al, 1993; Glynne-Jones et al, 1996).
Overexpression of the EGFR is also associated with a worse
clinical prognosis (Gullick, 1991; Modjtahedi and Dean, 1994). To
date, all prostate cancer cell lines tested (including DU145, PC3,
LNCaP, ALVA101 and ARCaP) express increased EGFRs (Liu
et al, 1993; Glynne-Jones et al, 1996; Zhau et al, 1996). The latter
cell line is highly invasive and metastatic, and has greatly
increased EGFRs (Zhau et al, 1996). Most of these cell lines are
growth-stimulated by EGF and TGF-a in culture (Davies and
Eaton, 1989; Ching et al, 1993), and growth-inhibited by EGFR
antibodies (Ennis et al, 1989; Mendelsohn, 1992). Moreover,
recent data indicate that chimeric monoclonal EGFR antibodies
can significantly inhibit the growth of DU145 and PC3 cell
xenografts in nude mice (Prewett et al, 1997). Analysis of the
responses to EGF and TGF-a in the androgen-independent DU145
and PC3 cell lines which overexpress EGFRs suggests that part of
the progression to hormone-independence involves a ‘switch’ in
secretion from EGF to TGF-a (Ching et al, 1993), and develop-
ment of an autocrine loop. Evidence supporting the existence of an
autocrine loop involving TGF-a and the EGFR has been obtained
in prostate carcinoma specimens (Glynne-Jones et al, 1996), as
well as in prostate cancer cell lines (Ching et al, 1993; Liu et al,
1993). In addition, secretion of TGF-a changes from paracrine to
autocrine in late-stage disease, which may contribute to the refrac-
tory nature of these tumours to hormonal therapy (Connolly and
Rose, 1990, 1991). Taken together, these data indicate that the
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Summary The epidermal growth factor receptor (EGFR) plays an important role in the development and progression of prostate cancer and
its overexpression is associated with decreased survival. With progression, prostate cancer cells switch from epidermal growth factor (EGF)
to transforming growth factor a (TGF-a) synthesis, which contributes to autocrine growth and unrestrained proliferation. To define the
molecular mechanisms involved in the regulation of EGFR expression by EGF and TGF-a we studied three human prostate cancer cell lines,
androgen-responsive (LNCaP) and -unresponsive (DU145 and PC3). Here we show that TGF-a stabilized EGFR mRNA two- to threefold in
all three cell lines, whilst EGF stabilized EGFR mRNA ~ twofold in LNCaP and DU145 cells, but not in PC3 cells. Both ligands increased
EGFR transcription in LNCaP and DU145 cells, with less effect in PC3 cells. In all three cell lines EGF reduced total EGFR protein levels more
than TGF-a, but this was associated with a greater increase in de novo protein synthesis with EGF compared to TGF-a. Only EGF, however,
shortened EGFR protein stability (half-life decreased from 5 h to 120 min), resulting in rapid disappearance of newly synthesized EGFR
protein. Both ligands increased total LNCaP and DU145 cell numbers. These studies demonstrate that the EGF- and TGF-a-induced
upregulation of EGFR mRNA and protein in human prostate cancer cell lines is complex and occurs at multiple, transcriptional and
post-transcriptional levels. Taken together, these data provide novel insight into the molecular mechanisms by which TGF-a would
preferentially maintain an autocrine loop in human prostate cancer cells. Furthermore, this work suggests that in human prostate cancer
cells ligand-specific differential intracellular trafficking of the EGFR plays a major role in regulating its expression.
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Relatively little is known about the molecular mechanisms
involved in the regulation of EGFR mRNA and protein expression
by EGFR and TGF-a, and their complex relationship with
androgen in prostate cancer cells. A decrease in EGFR binding
sites has been observed with EGF in some studies, but the mecha-
nism of the decrease has not been fully elucidated (Hanover et al,
1985; Turkeri et al, 1994). Modulation of EGFR expression by
androgens is complex. Androgens have been shown to up-regulate
(Schuurmans et al, 1988, 1991) or down-regulate (Traish and
Wotiz, 1987; Connolly and Rose, 1990) EGFR expression. For
example, dihydrotestosterone (DHT) has been shown to up-
regulate EGFR mRNA ~ two-fold in androgen-responsive
ALVA101 prostate cancer cells (Liu et al, 1993). In studies using
the PC3 cell line stably transfected with the androgen receptor
(AR), DHT increased EGFR mRNA and protein expression ~ two-
fold (Brass et al, 1995). In non-prostate human carcinoma cells
there is considerable evidence for regulation of EGFR expression
at the post-transcriptional level: (i) EGF increases EGFR mRNA
in breast MDA-468 and epidermoid KB cells by increasing the
stability of the mRNA (Jinno et al, 1988) and (ii) thyroid hormone
dramatically reduces EGFR mRNA stability in A431 cells
(Kesavan et al, 1991). The possibility that stabilization of EGFR
mRNA may play an important role in the development of the
TGF-a-EGFR autocrine loop in prostate cancer cells has not been
explored.
To better define the molecular mechanisms involved in regula-
tion of EGFR expression by EGF and TGF-a and the role of the
EGFR pathway in prostate cancer cell growth, we studied three
human prostate cancer cell lines (LNCaP, DU145 and PC3). Here
we show that EGF and TGF-a differentially regulate EGFR
mRNA and protein synthesis, and that the regulation is exerted at
transcriptional and multiple post-transcriptional levels. At the
mRNA level, the predominant effect of TGF-a is to stabilize
EGFR mRNA, whilst EGF predominantly increases EGFR trans-
cription. Interestingly, TGF-a reduces the stability of EGFR
protein less than EGF. This supports a central role for TGF-a in
the ‘switch’ that promotes development and maintenance of the
autocrine TGF-a–EGFR loop in these cells. Both ligands induced
proliferation of LNCaP and DU145 cells; however, TGF-a
induced significantly more proliferation than EGF at 24 h in
LNCaP cells. Thus, the TGF-a–EGFR pathway plays an impor-
tant role in the proliferative response in androgen-responsive and -
unresponsive prostate cancer cells. These data define novel
differences in the molecular mechanisms of action of EGF and
TGF-a in human prostate cancer cells, and provide a molecular
mechanism for the preferential role of TGF-a in the maintenance
of the autocrine loop. Furthermore, they suggest that ligand
-specific differential intracellular trafficking plays a major role in
regulating EGFR expression in these cells.
MATERIALS AND METHODS
Cell lines and reagents
Cell lines were obtained from ATCC (Rockville, MD, USA).
LNCaP, DU145 and PC3 cells were grown and maintained in
RPMI-1640 (minus phenol red) media supplemented with 10%
non-heat-inactivated fetal calf serum (NHI-FCS) (Gibco-BRL,
Sydney, Australia) and 1% Pen/Strep (100 U ml21 penicillin,
100 mg ml21 streptomycin) at 378C and 5% carbon dioxide. For
experiments, cells were grown to 70% confluence in 60 mm
dishes, serum starved for 24 h and the effect of EGF (0.25–16 nM),
TGF-a (0.25–16 nM) (Promega Corp., Madison, WI, USA), DHT
(10 nM) and cycloheximide (CHX) (10 mg ml21) (Sigma, St Louis,
MO, USA) on EGFR expression was determined.
Cell proliferation assays
Equal numbers of cells were plated in triplicate (~1 3 104 per
well), serum starved for 24 h and exposed to EGF or TGF-a
(4 nM) and/or DHT (10 nM) for various time intervals. The cells
were harvested by trypsinizing in 100-ml phosphate-buffered
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Figure 1 Schematic of EGFR mRNA. Line diagram of EGFR mRNA depicting 5¢-UTR, coding region, 3¢-UTR and poly(A) tail. For multiplex PCR the primers
EGFR-11 (3951) and EGFR-13 (4213) in the AU-rich region (AU-R) of the 3¢-UTR were used. An ~ 1 kb probe (2950–3972) from the EGFR coding region was
used in the Northern analysis. Also shown are the positions of the AU-R regions (AUUUA) in the 3¢-UTR of EGFR mRNA
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5532saline (PBS) and cell numbers counted using a haemocytometer
under 100 3 magnification of a Leitz Wetzlar microscope.
cDNA probes
An ~ 1 kb BamH1/HindIII fragment containing the 3¢ end of
the coding region and 131 bp from the 3¢-untranslated region
(3¢-UTR) of the EGFR cDNA (see Figure 1) was random primed
using 32P dCTP (3000 Ci mmol21, Amersham, Australia) and used
to probe for EGFR mRNA. A 1.1 kb EcoR1/BamH1 fragment
from a plasmid encoding rat 18S ribosomal RNA was labelled
with  32P dCTP and used as a probe for normalization.
RNA isolation and Northern analysis
Cells were lysed in 4 M guanidinium isothiocyanate (GTC) (ICN)
and total RNA isolated using phenol–chloroform extraction. RNA
(10–15 mg) was size fractionated on a 1% agarose–formaldehyde
gel, transferred and UV cross-linked to Hybond-N1 membrane
(Amersham, Australia), prehybridized and hybridized in
formamide buffer overnight at 428C with a 32P dCTP labelled
EGFR cDNA probe with at least 106 cpm ml21. The membrane
was washed and analysed by autoradiography using Kodak EM-1
film at 2808C and quantitated using ImageQuant software
(Molecular Dynamics). For normalization, the membranes were
stripped by boiling in 1% sodium dodecyl sulphate (SDS) for
10 min and reprobed with a rat 18S ribosomal RNA cDNA probe.
mRNA turnover studies
Cells were grown to 70% confluence in 60-mm dishes in standard
media, serum starved for 24 h and treated with EGF, TGF-a or
CHX for 8 h (controls were untreated) followed by the addition
of the transcription inhibitor actinomycin D (5 mg ml21, Sigma,
St Louis, MO, USA). Total RNA was isolated from the cells at 0,
2, 4, 6, 8 and 12 h time intervals and subjected to Northern
analysis or multiplex reverse transcription polymerase chain
reaction (RT-PCR) (described below). mRNA half-life was
determined using linear regression analysis.
Reverse transcription
Total RNA (1–4 mg) was reverse transcribed with oligo dT using
AMV-reverse transcriptase (Promega Corp., Madison, WI, USA)
at 428C for 1 h. The first strand cDNA was stored at 48C and used
as template for subsequent multiplex PCR.
Oligonucleotides for multiplex PCR
EGFR primers were designed from the 3¢UTR of EGFR flanking
the AU-rich region (Figure 1) which amplified a 262 bp frag-
ment. EGFR-11 (3951–3985): 5¢-GACTAGATCTCCACCGAG-
GATAGTATGAGCCCTA; EGFR-13 (4213–4183): 5¢-CTAGA-
GATCTAAGCTTCTTCCTTGTTGGAA. The primers used for
normalizing were either from human b-actin cDNA generating
an amplicon of 202 bp – b-actin sense (1298–1318): 5¢-GCCAA-
CACAGTGCTGTCTGG;  b-actin antisense (1500–1481):
5¢-TACTCCTGCTTGCTGATCCA – or GAPDH primers from
a human cDNA lung cancer cell amplifying 309 bp fragment
on PCR – GAPDH sense (60–88): 5¢-GTGAAGGTCGGAGT-
CAACG; GAPDH antisense (369–349): 5¢-GGTGAA-
GACGCCAGTGGACTC. Oligonucleotides were obtained from
Biotech International Ltd, Australia. Multiplex PCR was
performed at 948C denaturing, 588C annealing and 728C extension
for 35 cycles in a Corbett FTS 320, Australia, thermal cycler using
50–100 ng each primer for 25 ml reaction volume. The bands were
resolved on a 3.5% agarose (ScientifiX, Australia) gel and
quantitated using ImageQuant software.
Nuclear run-on transcription assay
Exponentially growing cells were treated with EGF or TGF-a for
6–8 h. Cells were washed twice with PBS and trypsinized. Nuclei
were isolated in the presence of NP40, centrifuged briefly, resus-
pended in nuclear storage buffer (50 mM Tris–HCl, pH 8.0, 40%
glycerol, 0.1 mM EDTA, 0.1 mM DTT) and stored in Nunc vials in
liquid nitrogen. For the transcription assay, the method used was as
described (Ausubel et al, 1994). Membranes were analysed by
PhosphorImager and quantitated using ImageQuant software.
Anti-phosphotyrosine ECL Western
This was performed as previously described (Tilbrook et al, 1996).
Briefly, cells were serum starved for 24 h, exposed to 1 nM, 4 nM
and 16 nM EGF or TGF-a for different (0–60 min) time periods,
washed and lysed in anti-phosphotyrosine lysis buffer and the
lysate incubated with 2 mg sheep polyclonal anti-human EGFR
antibody (Upstate Biotechnology, USA). After overnight adsorp-
tion onto protein A beads the eluate was subjected to 7%
SDS-PAGE and immunoblotted prior to incubation with a 1:1000
dilution of antiphosphotyrosine IgG2bk (Upstate Biotechnology,
USA) followed by a 1:5000 dilution of anti-mouse HRP antibody.
Protein was visualized by enhanced chemiluminescence (ECL;
Amersham, UK) and bands quantitated using a Kodak Digital
DCS-420c camera and ImageQuant software. To normalize for
protein loading on the gel, membranes were incubated with
primary and secondary antibodies exactly as described below for
the EGFR Western blot assay.
Western blot assay
Cells were serum starved for 24 h and treated with EGF or TGF-a
for 6–8 h, harvested and lysed in ice-cold lysis buffer (1% Triton
X-100, 20 mM Tris–HCI pH 7.4, 1 mM EDTA). The lysate was
incubated for 10 min on ice, centrifuged at 1500 g for 10 min at
48C, and the supernatant snap-frozen and stored at 2808C. Total
protein concentrations were determined using the Bio-Rad protein
assay kit. Protein (15–20 mg per lane) was electrophoresed on 7%
SDS-PAGE gels and transferred to nitrocellulose membrane. The
membrane was blocked with 5% skim milk in 1 3 TBS-T (20 mM
Tris–HCl pH 7.4, 150 mM sodium chloride, 0.1% Tween-20) at
48C overnight, incubated with a 1:2000 dilution of a sheep poly-
clonal anti-human EGFR antibody (Upstate Biotechnology, Santa
Cruz, CA, USA) for 1 h at room temperature, and then washed and
incubated with horseradish peroxidase-conjugated anti-sheep goat
IgG antibody (1:2000 dilution) (Amersham, UK). The protein was
visualized and bands quantitated as above.
Metabolic labelling of cells
Cells were serum starved for 24 h and exposed to 4 nM EGF or
TGF-a for 6 h. For immunoprecipitation experiments, media were
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Australia) containing 2% FCS for 2 h and labelled for 1 h 6 EGF
or TGF-a with 200 mCi of Promix L35S-methionine/cysteine
(Amersham, Australia) as described (Beguinot et al, 1984).
Briefly, cells were washed, lysed in lysis buffer and the lysate
(2 3 107 cpm) was incubated with 3 mg sheep polyclonal anti-
human EGFR antibody (Upstate Biotechnology, USA) for 2 h at
48C and the immunoprecipitate adsorbed onto protein A Sepharose
beads. Beads were washed and the eluate subjected to 7%
SDS-PAGE. To estimate the rate of EGFR protein synthesis, cells
were treated as above except that EGFR protein was isolated at
various time points after addition of the radioisotope. For protein
decay assays, the L35S-methionine/cysteine was replaced with
media  6 EGF or TGF-a after 1 h, and EGFR protein determined
at different time intervals, thereafter.
Statistical analysis
Statistical analysis was performed using the Student’s unpaired 
t-test and results are shown at the 0.05% level of significance.
RESULTS
EGF and TGF-a up-regulate EGFR mRNA in androgen-
dependent and -independent prostate cancer cell lines
In preliminary experiments we evaluated the biological potency of
each ligand by determining the concentration of EGF and TGF-a
that produced comparable levels of phosphotyrosine activation of
the EGFR in each cell line. Incubation of LNCaP and DU145 cells
with 25 ng ml21 (4 nM) EGF and 20 ng ml21 (4 nM) TGF-a respec-
tively, induced an equivalent level of EGFR tyrosine phosphoryla-
tion at 15 and 30 min time points (Figure 2). Thus, for subsequent
experiments we used 4 nM EGF and 4 nM TGF-a unless otherwise
specified. To determine the effect of dose–response for each ligand
on EGFR mRNA, cells were incubated with either EGF (0.25–
16 nM), TGF-a (0.25–16 nM) or CHX (10 mg ml21) for various
time intervals, total RNA extracted and analysed by either
Northern hybridization or semi-quantitative multiplex RT-PCR. A
major EGFR RNA species of 10-kb (the 5.6-kb band was very
faint or absent) was identified in Northern blots using androgen-
independent DU145 and PC3 cell lines (Figure 3), as has been
described by others (Morris and Dodd, 1990; Ching et al, 1993).
EGFR mRNA was undetectable in LNCaPs by Northern analysis
due to the low abundance of the message; however, the EGFR
mRNA was readily detected by multiplex RT-PCR amplification
in these cells. Maximum expression of EGFR mRNA was found at
6–8 h in time course experiments at an optimum ligand concentra-
tion of 4 nM EGF and TGF-a. Preliminary experiments also deter-
mined that the increase in EGFR mRNA expression induced by 4
nM EGF and TGF-a was similar using cells cultured in either 10%
FCS or in serum-free conditions (not shown). Thus, with subse-
quent experiments, cells were serum starved for 24 h prior to
addition of ligand. In LNCaP cells, EGF and TGF-a induced a
significant three- to fourfold and two- to threefold up-regulation
of EGFR mRNA respectively (Figure 3). EGFR mRNA was
significantly up-regulated by six- to eightfold and three- to four-
fold in DU145 cells, and two- to threefold and fivefold in PC3
cells with EGF and TGF-a respectively (Figure 3). The ligand-
induced increase in EGFR mRNA was mostly back to basal levels
by 12 h (data not shown). EGF had greatest effect on EGFR
mRNA in LNCaP and DU145 cells whilst TGF-a produced the
largest increase in PC3 cells (Figure 3). When all three cells lines
were incubated with CHX, EGFR mRNA increased five- to
sixfold, suggesting involvement of a labile protein in the regula-
tion of EGFR mRNA turnover (data not shown). These results
demonstrated ligand- and cell-specific regulation of EGFR mRNA
expression in each of the three prostate cancer cell lines.
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Figure 2 Phosphorylation of the EGFR by EGF and TGF-a. LNCaP and
DU145 cells were serum starved for 24 h, incubated with 4 nM EGF or TGF-a
for 15 min, the lysate immunoprecipitated with EGFR antibody (see Materials
and Methods), electrophoresed on a SDS-PAGE gel, transferred to
nitrocellulose, before immunoblotting with either an antiphosphotyrosine or
EGFR antibody and detection of the bands by ECL. EGFR-P, tyrosine
phosphorylated EGFR detected using the antiphosphotyrosine antibody.
Total EGFR, EGFR protein detected using EGFR antibody. CON, control
Figure 3 Effect of EGF and TGF-a on regulation of EGFR mRNA in
LNCaP, DU145 and PC3 cells. Total RNA extracted from cells treated for 8 h
with 4 nM of either EGF or TGF-a was fractionated on 1% agarose,
transferred to nylon membrane and hybridized to a 32P labelled EGFR-
specific cDNA probe for DU145 and PC3 samples. The blot was normalized
with a rat 18S cDNA probe. A 10 kb EGFR and 18S message were
quantitated by PhosphorImager. For LNCaP cells, 1 mg of total RNA was
reverse transcribed with AMV-RT and subjected to multiplex PCR with EGFR
and GAPDH primers. The bands were quantitated using ImageQuant
software. Each value in the bar chart is shown relative to an arbitrary value of
1 at zero time and is the mean of at least three experiments performed in
duplicate. Error bars denote standard error of the mean. The top panel
shows bands from a representative experiment. * represents significant
difference relative to control
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TGF-a in prostate cancer cells
To establish whether the observed EGF- and TGF-a-induced
increase in EGFR mRNA expression was due to a change in EGFR
mRNA turnover, we used actinomycin D (ActD) pulse chase.
Preliminary studies on cell survival in the presence of ActD using
trypan blue staining showed that . 90% cells survived 24 h post-
treatment (not shown). Cells were incubated 6 EGF or TGF-a,
ActD added and EGFR mRNA analysed at various time intervals
by either Northern (DU145 and PC3 6 EGF) or multiplex RT-PCR
analysis (LNCaP 6 EGF/TGF-a; DU145 and PC3 6 TGF-a).
Either b-actin (DU145) or glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) (LNCaP and PC3) primers were used in the
multiplex PCR for normalizing. Our analysis showed that TGF-a
stabilized EGFR mRNA half-life from ~ 4 h to . 12 h in LNCaP
(Figure 4A) and DU145 (Figure 4B) cells, and to ~ 8 h in PC3 cells
(Figure 4D). EGF stabilized EGFR mRNA half-life from ~ 4 to
~ 7 h in LNCaP cells (Figure 4A) and from ~ 4 to . 10 h in
DU145 cells (Figure 4C). Little change was observed in PC3 cells
with EGF on Northern analysis (Figure 4E). TGF-a induced a
more pronounced stabilization of EGFR mRNA in all three cell
lines. Thus, EGF and TGF-a stabilized EGFR mRNA at least
twofold in all three cell lines except in PC3 cells.
Regulation of EGFR transcription by EGF and
TGF-a in prostate cancer cells
In order to determine the transcriptional contribution to the
EGF- and TGF-a-induced modulation of the EGFR mRNA,
nuclear run-on assays were performed. Figure 5 shows that EGF
and TGF-a increased EGFR mRNA transcription ~ four- and~
twofold in both LNCaP and DU145 cells respectively. In contrast,
PC3 cells showed a smaller increase in transcription in response to
either ligand (Figure 5). These studies indicated that the predomi-
nant effect of EGF to increase EGFR mRNA in LNCaP, DU145
and PC3 cells was at the transcriptional level. For TGF-a,
however, the major effect was at the post-transcriptional level,
inducing substantial increases in EGFR mRNA stability with a
smaller relative increase in transcriptional rate.
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Figure 4 Effect of EGF and TGF-a on EGFR mRNA stabilization. Cells (LNCaP, DU145, PC3) were grown to 70% confluence, treated with 4 nM EGF or
TGF-a for 8 h and chased with 5 mg ml21 actinomycin D for various time intervals. Total RNA was extracted and was subjected to either Northern analysis (C, E)
or multiplex RT-PCR (A, B, D) and quantitated as described in Materials and Methods. The linear regression analysis of EGFR mRNA half life is representative
of at least three experiments performed in duplicate. The top panels show bands from individual representative experiments. CON, control. (A) LNCaP cells.
Multiplex PCR of AMV-reverse transcribed total RNA using EGFR and GAPDH primers. (B) DU145 cells and TGF-a. Multiplex PCR of AMV-reverse transcribed
total RNA using EGFR and b-actin primers. (C) DU145 cells and EGF. Total RNA (12 mg) extracted from DU145 cells was analysed by Northern blotting using
32P labelled EGFR-specific and rat 18S cDNA probes. (D) PC3 cells and TGF-a. Multiplex PCR of AMV-reverse transcribed total RNA using EGFR and GAPDH
primers. (E) PC3 cells and EGF. Total RNA (12 mg) extracted from PC3 cells was analysed by Northern blotting using 32P labelled EGFR-specific and rat
18S cDNA probesEGF and TGF-a down-regulate total EGFR protein in a
ligand-specific manner
To examine whether the increase in EGFR mRNA was associated
with an increase in receptor protein, cells were incubated 6 EGF
or TGF-a for 6–8 h and EGFR protein analysed by immunoblot-
ting and ECL. The total amount of EGFR protein was at least
fivefold greater in untreated samples from DU145 and PC3 cells
compared to LNCaP cells (Figure 6A, compare control lanes in
LNCaP and DU145). EGF induced a significant decrease in total
EGFR protein in LNCaP and PC3 cells (to 14%, and 32% of
control respectively), and to a lesser extent in DU145 cells (62%)
(Figure 6A). In marked contrast, EGFR protein levels were little
changed by TGF-a in LNCaP and DU145 cells (89% and ~ 110%
of control, respectively), but showed a significant decrease in
PC3 cells (68% of control) (Figure 6A). Thus, major differences
exist in the regulation of EGFR protein in these cells, with EGF
significantly reducing total EGFR protein compared to TGF-a.
Further, it is evident that the EGF- and TGF-a-induced increase in
EGFR mRNA described above is not associated with a significant
increase in total EGFR protein.
EGF and TGF-a increase de novo EGFR protein
synthesis in prostate cancer cell lines
Our data comparing the regulation of total EGFR protein levels in
these prostate cancer cell lines suggested that each ligand was
exerting major, yet distinct, effects on EGFR expression at the
post-transcriptional level. We next investigated whether the up-
regulation of EGFR mRNA was associated with an increase in de
novo EGFR protein synthesis. Cells treated with EGF or TGF-a
for 7 h were incubated with L35S-methionine/cysteine for 1 h and
newly synthesized EGFR protein was immunoprecipitated using a
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Figure 6 EGF and TGF-a differentially regulate EGFR protein in LNCaP, DU145 and PC3 cells. (A) Total protein assessed by immunoblotting. Total protein
was extracted from cells 6 EGF or TGF-a, and 20 mg protein/lane was electrophoresed on 7% SDS-PAGE gels, immunoblotted with a sheep anti-human EGFR
polyclonal antibody, and detected using enhanced chemiluminescence (ECL). Values shown are relative to an untreated sample of 1 (control) and are
representative of at least three experiments performed in duplicate. Error bars denote standard error of the mean. The top panel is representative of an
individual experiment. * represents significant difference relative to control. (B) De novo protein synthesis by immunoprecipitation. LNCaP, DU145 and PC3 cells
were metabolically labelled with L35S-methionine/cysteine and incubated 6 EGF or TGF-a for 8 h. Samples were immunoprecipitated using a sheep polyclonal
anti-human EGFR antibody and Protein A beads. Samples were electrophoresed on a 7% SDS-PAGE gel, dried and quantitated by PhosphorImager. Values
shown are relative to an untreated sample of 1 (control) and are representative of at least three experiments performed in duplicate. Error bars denote standard
error of the mean. The top panel is representative of an individual experiment. * represents significant difference relative to controlsheep anti-human EGFR polyclonal antibody as described in
Materials and Methods. Figure 6B shows that in LNCaP, DU145
and PC3 cells newly translated EGFR protein levels significantly
increased to 1.5-, two- and ~ twofold with EGF, but only 1.2-,
1.5- and 1.3-fold with TGF-a respectively. These data confirmed
that the increased EGFR mRNA was associated with an increased
synthesis of new EGFR protein. However, although each ligand
increased new EGFR protein synthesis, the increase with EGF was
significantly greater than with TGF-a. The combination of an
EGF-induced increase in new protein synthesis associated with
markedly reduced total protein levels suggested that EGF was
exerting an additional major effect at the translational and/or
post-translational level.
EGF and TGF-a differentially regulate EGFR protein
turnover in prostate cancer cells
To further define the regulation of EGFR protein turnover, we
performed time course studies of de novo EGFR synthesis. LNCaP
and DU145 cells were incubated with L35S-methionine/cysteine
for various time intervals (10 min to 6 h) before immunoprecipita-
tion with EGFR antibody, and analysed by SDS-PAGE. Figure 7A
and B shows that within 10 min of the addition of EGF a change in
rate of EGFR protein synthesis was detectable, which reached a
maximum of twofold increase above control by 60 min in both
LNCaP (Figure 7A) and DU145 (Figure 7B) cells. However, by
2 h the level of synthesis in control LNCaP and DU145 cells was
equal to that in cells treated with EGF. Further, by 6 h the rate of
synthesis of EGFR in control cells was at least twofold greater
than EGF-treated cells in both LNCaP and DU145 cells. Thus, in
contrast to the effect of EGF, in control cells EGFR protein
synthesis increased gradually over the 6-h incubation. These data
suggest that although EGF increases the de novo protein synthesis
rate within the first hour of treatment, the increase is not sustained.
This may in part reflect that with the longer times of incubation,
we were measuring both synthetic rate and also a component of
EGFR decay. We next examined the effect of TGF-a on EGFR
protein synthesis in LNCaP and DU145 cells. Figure 7C and D
shows that TGFa increased EGFR protein synthesis ~ twofold in
LNCaP cells at 120 min (Figure 7C) but little difference was
recorded in DU145 cells over control (Figure 7D). Moreover, the
EGFR protein levels were sustained and did not decrease below
control at 6 h as observed with EGF.
A marked disparity still remained between the EGFR synthetic
rate and the total protein data in Figure 6A. To address the possi-
bility that EGF and TGF-a differentially modulated EGFR protein
stability, L35S-methionine/cysteine pulse chase studies were
performed. LNCaP and DU145 cells 6 EGF or TGF-a were incu-
bated with 35S-methionine for 60 min, after which the cells were
replenished with regular medium. EGFR protein was immunopre-
cipitated after various time intervals (0, 30, 60, 120 min, 5 h) and
resolved by SDS-PAGE as above. Results in Figure 8A and B
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Figure 9 Regulation of LNCaP, DU145 and PC3 cell proliferation by EGF, TGF-a and DHT. Cells [(LNCaP (A), DU145 (B) and PC3 (C)] were serum starved
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standard deviation. * represents significant difference relative to controlshows that EGF induced rapid disappearance of EGFR protein in
LNCaP and DU145 cells with a half-life of ~ 120 min, compared
to ~ 5 h in control. This rapid decrease in EGFR protein stability
within 120 min after treatment with EGF would explain, in part,
the low levels of total EGFR protein observed in immunoblotting
(Figure 6A). Interestingly, when LNCaP and DU145 cells were
treated with TGF-a the rate of disappearance of EGFR protein did
not change in either cell line (see Figure 8A, B). The half-life of
the EGFR protein remained ~ 5 h in the presence and absence
of TGF-a. These results emphasize the complexity of the post-
transcriptional control of EGFR expression induced by each ligand.
Ligand-induced cell proliferation of prostate cancer
cells
To monitor the ligand-induced effect on cell proliferation, LNCaP,
DU145 and PC3 cells were serum starved for 24 h, treated with
EGF or TGF-a and/or DHT for different time intervals,
trypsinized and counted. At 24 and 48 h both EGF and TGF-a
increased cell numbers in androgen-dependent LNCaP cells
significantly above control (~ 1.5–2-fold), and also above the
increase induced by DHT (~ 1.2-fold above control) at 48 h
(Figure 9A). The combination of DHT and EGF was additive
resulting in significant proliferation (~ 1.8-fold) above control.
However, the response to DHT and TGF-a together was no greater
than with TGF-a alone. In the androgen-independent DU145 cell
line, EGF and TGF-a both significantly increased cell prolifera-
tion one- to twofold above control levels at 24 and 72 h (Figure
9B). DHT alone or in combination with EGF or TGF-a had no
positive effect on cell proliferation (Figure 9B). In PC3 cells
neither ligand induced growth above control at 24 or 48 h (Figure
9C). These results indicate that EGF and TGF-a induce significant
cell proliferation in both androgen-dependent (LNCaP) and
androgen-independent (DU145) cells. Furthermore, it illustrates
the potential for the EGF/TGF-a–EGFR pathway to contribute to
prostate cancer cell at both relatively early (androgen-responsive)
and more advanced (androgen-unresponsive) stage disease.
DISCUSSION
To investigate the molecular mechanisms involved in the modula-
tion of EGFR-mediated growth in prostate cancer, we examined
the effect of EGF and TGF-a on the regulation of EGFR expres-
sion in androgen-dependent (LNCaP) and -independent (DU145
and PC3) prostate cancer cell lines. Our results demonstrate that
EGF and TGF-a induce distinct mechanisms to up-regulate EGFR
expression, which are both ligand- and cell-specific (see Table 1).
With the exception of PC3 cells, each ligand differentially up-
regulated both EGFR mRNA stability and transcription. In LNCaP
and DU145 cells, EGF stabilized EGFR mRNA ~ twofold,
whereas no significant effect was observed in PC3 cells. TGF-a,
however, stabilized EGFR mRNA ~ twofold greater than EGF in
all three cell lines. The converse was found at the transcriptional
level, where EGF increased transcription in LNCaP and DU145
cells ~ twofold greater than TGF-a. Thus, the predominant effect
of TGF-a at the mRNA level is post-transcriptional in all three cell
lines, whereas for EGF the major contribution is at the transcrip-
tional level (Table 1). The CHX-induced increase in EGFR mRNA
indicated that a labile protein may be involved in the maintenance
of EGFR mRNA turnover. Furthermore, it raised the possibility
that regulation of EGFR mRNA decay may be closely coupled to
its translation. Several examples have been previously described
linking mRNA decay to translation (Peltz and Jacobson, 1992;
Sachs, 1993; Decker and Parker, 1994).
mRNA decay is now recognized as a major control point in the
regulation of gene expression. Our results represent the first to
demonstrate the importance of changes in EGFR mRNA turnover
in the prostate. Previous reports in other tissues have described
changes in EGFR mRNA stability in response to various ligands.
The EGF-induced increase in EGFR mRNA in breast MDA-468
(Fernandez-Pol et al, 1989) and epidermoid KB (Jinno et al, 1988)
cancer cells is, in part, due to increased stability of EGFR mRNA.
In addition, thyroid hormone dramatically reduces EGFR mRNA
stability in A431 cells (Kesavan et al, 1991). The mechanisms
involved in facilitating increased stability of the EGFR mRNA in
prostate cancer cells are unknown but may involve RNA–protein
interactions between cis-acting mRNA stability modifying regions
and trans-acting EGFR RNA binding proteins. Many short-lived
mRNAs, including several of the cytokines and proto-oncogenes,
contain an AU-rich region (AU-R, typically AUUUA repeats) in
the 3¢-UTR which can confer metabolic instability by targeting
these mRNAs for rapid degradation (Greenberg and Belasco
1993). Interestingly, the 3¢-UTR of EGFR mRNA contains two
AU-rich regions and three AUUUA pentamers (see Figure 1). One
or more of these motifs may represent a target for growth factor-
regulated AU-rich RNA binding factors (AUBFs). This EGFR
mRNA–protein complex may function to protect the mRNA
against degradation, thereby increasing the mRNA stability in the
presence of ligand. A more stable EGFR mRNA would promote
increased EGFR protein production and cellular proliferation, and
favour the development of an autocrine loop. Current studies are
underway to define the cis—trans EGFR RNA–protein interactions
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Table 1 Differential regulation of EGFR expression by EGF and TGF-a in LNCaP, DU145 and PC3 human prostate cancer cells
Total Total De novo EGFR mRNA EGFR Cell
mRNA protein protein stability transcription proliferation
LNCaP 4 0.14 1.5 .2 4 1.5} DU145 6 0.62 2 2 4 1.5 EGF
PC3 2 0.32 2 1 2 1
LNCaP 2 0.89 1.2 3–4 2 2 } DU145 2 1.1 1.5 3–4 2 2 TGF-a
PC3 5 0.68 1.3 1.2 1.5 1
Regulation of EGFR expression at transcriptional, post-transcriptional and translational levels by EGF and TGF-a in androgen-dependent (LNCaP)
and -independent (DU145, PC3) prostate cancer cell lines. Values are relative to a control level of 1 prior to ligand addition.in human prostate cancer cells that control EGFR mRNA
stability.
The mechanisms by which EGF and TGF-a produced low
levels of total EGFR protein, in the context of elevated levels of
EGFR mRNA in LNCaP, DU145 and PC3 cells proved to be of
considerable interest. The down-regulation in total protein with
EGF was most pronounced in LNCaP and PC3 cells. In marked
contrast, there was only a slight change in total EGFR protein
levels in LNCaP and DU145 cells with TGF-a. The increase in
EGFR mRNA levels and stability was associated with increased
synthesis of EGFR protein (see Table 1). However, pulse chase
labelling studies indicated that the down-regulation of EGFR
protein induced by EGF was the result of rapid disappearance of
the receptor protein, which was not compensated for by the
increased level of EGFR mRNA, its stabilization or enhanced
translation of the protein. Thus, EGF preferentially induced rapid
EGFR protein decay in these human prostate cancer cell lines.
Increased EGFR mRNA expression with decreased protein
levels has been previously reported in various cell types in the
presence of exogenous EGF. For example, in the WB cell line
from rat hepatic epithelium, a three- to fivefold EGF-induced
increase in EGFR mRNA was associated with a down-regulation
in EGFR protein (Earp et al, 1986). EGF has also been reported to
down-regulate EGFR protein in human epidermoid A431 and KB
cells (Kawamoto et al, 1983; Lifshitz et al, 1983; Clark et al, 1985)
and breast cancer cells (Kudlow et al, 1986; Bilous et al, 1992). In
prostate tumours high levels of EGFR mRNA have been reported
to vary inversely with EGFR protein levels (Turkeri et al, 1994).
Further, although EGFR mRNA has been detected at higher levels
in prostate cancer specimens (Ching et al, 1993), exogenous EGF
has been shown to down-regulate EGFR protein expression
(Maddy et al, 1989; Turkeri et al, 1994). The work presented here
adds support to these observations, defines the molecular mecha-
nisms involved and illustrates the differences between the action
of EGF and TGF-a at the post-transcriptional level.
Recent studies have provided insight into the pathways involved
in the intracellular trafficking of the EGFR, and similar molecular
mechanisms may be operative in prostate cancer cells. Recent
reports suggest that alternative intracellular routing of the EGFR
and its ligands may contribute to a broad range of signal trans-
duction, and consequently have a profound impact on cellular
proliferation. Previous studies demonstrated that EGF induced
internalization of the EGF–EGFR complex to clathrin-coated pits,
movement to receptosomes and delivery to lysosomes facilitating
complete degradation of EGFR within 120 min (Beguinot et al,
1984, 1985). Subsequent studies indicated that ligand occupancy
of the receptor was critical for efficient targetting. Wiley at al
(1991) correlated the EGF-induced EGFR down-regulation to
occupancy-induced endocytosis. This was due to an increase in
receptor targetting to lysosomes and subsequent degradation by
increasing the pool of receptors at steady state. Interestingly,
ligand-occupied kinase-active EGFRs were internalized through a
high affinity endocytic system at rates up to ten times faster than
empty receptors, suggesting a central role for ligand in the
signalling. Several studies have since examined differences
between the effects of EGF and TGF-a on receptor degradation.
EGF was shown to be resistant to dissociation from the EGFR in
endosomes (French et al, 1995), whilst TGF-a rapidly dissociated
from the EGFRs (Ebner and Derynck, 1991) resulting in more
efficient targetting of EGFRs to lysosomes with EGF than with
TGF-a. This would lead to enhanced biological activity due to
repeated presentation of recycled EGFRs at the cell surface,
resulting in multiple rounds of signalling. Most recently,
Waterman et al (1998) demonstrated that EGF and TGF-a had
markedly different effects on receptor down-regulation in CHO
cells. They showed that EGF-stimulated EGFRs were destined for
rapid lysosomal degradation. In contrast, EGFRs bound by TGF-a
underwent rapid endocytosis but were shunted down a different
pathway leading to receptor recycling with only limited down-
regulation. Consistent with this, the mitogenic activity of TGF-a
was superior to that of EGF in this system, reinforcing the concept
that differential intracellular EGFR routing may play an important
role in the regulation of mitogenic signals.
Recent studies using a HeLa cell line defective in clathrin-
coated vesicles, illustrated the importance of this pathway for
intracellular EGFR trafficking (Vieira et al, 1996). In wild-type
HeLa cells, EGFR was endocytosed and degraded with a half-life
of 30 min. However, in these mutant HeLa cells, approximately
80% of the EGFRs were detected even after 2 h. The recent
discovery of a sorting protein, nexin-1 (SNX1), which sorts EGFR
to lysosomes (Kurten et al, 1996), provided clues to the potential
molecular mechanism(s) involved. Overexpression of SNX1
reduced EGFR expression at the cell surface in CV1 cells and
increased EGF-induced EGFR degradation. Whether SNX1 is
differentially regulated by EGF and TGF-a, and its role in prostate
cancer cells, is yet to be determined. However, our data are consis-
tent with the concept that EGF and TGF-a differentially regulate
intracellular EGFR trafficking. We propose that, in prostate cancer
cells, EGF preferentially diverts the internalized EGF–EGFR
complex to endosomes and lysosomes, whilst TGF-a dissociates
from the complex and recycles EGFR back to the cell membrane
(see Figure 10). Further work is in progress to investigate this
thesis.
The variety of erbB receptors (EGFR, erbB2, erbB3 and erbB4)
provides another level of complexity that adds to the diversity of
the erbB signalling network (Burden and Yarden, 1997). Each
ligand molecule is bivalent with a high affinity site for binding the
‘primary receptor’, and a low affinity site with broad specificity
that facilitates recruitment of other members of the erbB receptor
family into heterodimers, resulting in differential and effective
signalling (Tzahar et al, 1997). How this system might impact on
the observations that we found in the present study is yet to be
determined. However, based on the heterodimer capacity of the
erbB family, and the recent work of Waterman et al (1998) in
which Neu differentiation factor (NDF) has a similar effect to
TGF-a to drive erbB3 receptor recycling and result in a more
potent mitogenic response, elucidation of the mechanisms and role
of heterodimer partners in the intracellular signalling of human
prostate cancer cells may well provide new insight into mito-
genesis and cellular proliferation.
Although several groups have characterized a TGF-a–EGFR
autocrine loop in prostate cancer cells (Wilding et al, 1989;
Connolly and Rose, 1990; Liu et al, 1993; Xie et al, 1995), the
molecular mechanisms governing the development and mainte-
nance of the loop have not been determined. In both LNCaP and
DU145 cells, EGF and TGF-a are synthesized and secreted into
the medium. The regulation of EGF synthesis by androgens may
be altered in human prostate cancer. The weight of evidence
suggests that in LNCaP cells there is a change to TGF-a and
EGFR production, resulting in continuous autocrine stimulation of
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in androgen-insensitive DU145 cells, providing a case for support
of prostate cancer cell growth in part, by TGF-a, following
androgen withdrawal. Our data demonstrate that EGF and TGF-a
preferentially regulate expression at different steps of the EGFR
synthetic pathway. The net result of these effects is a greater
increase of EGFR protein concentration with TGF-a compared to
EGF. This would favour establishment of an autocrine loop in
these cells. Previous work has suggested that prostate cancer cells
undergo a ‘switch’ in secretion from EGF to TGF-a which is asso-
ciated with a poor prognosis (Ching et al, 1993; Steiner, 1993) and
more advanced disease. Our data are consistent with these clinico-
pathologic findings and they provide a molecular explanation why
autocrine secretion of TGF-a, rather than EGF, would lead to
sustained EGFR expression and increased prostate cancer cell
proliferation and growth.
EGF and TGF-a induced cell proliferation in LNCaP and
DU145 cells, but not in PC3 cells. Interestingly, the increase in cell
proliferation was significantly greater in LNCaP cells with EGF
and TGF-a than with DHT and there was no additive effect of
TGF-a when combined with DHT. These data are consistent
with others who have reported a ligand-induced increase in cell
proliferation in DU145 (Connolly and Rose, 1990, 1991) and in
LNCaP of ~ twofold with EGF and TGF-a, and ~ threefold with
the synthetic androgen, R1881 (Schuurmans et al, 1991).
However, our results differ from reports where TGF-a displayed
little response in LNCaP cells, yet increased PC3 cell growth by
35% (Hofer et al, 1991; Carruba et al, 1994). The differences that
we observed in proliferative responses to EGF and TGF-a
between the two EGFR overexpressing androgen-unresponsive
cell lines (DU145 and PC3) are also of note. For PC3 cells these
data suggest that growth proliferation (~ fourfold over 48 h) is
independent of EGF, TGF-a and androgens, and implicates
involvement of other growth factors, such as insulin-like growth
factor (IGF) (Steiner, 1993; Byrne et al, 1996), TGFb and fibro-
blast growth factor (FGF) (Steiner, 1993; Steiner and Barrack,
1992). However, PC3 cell proliferation is inhibited by antibodies to
TGF-a and EGFR, suggesting that the TGF-a–EGFR pathway may
be permissive for growth in these cells (Hofer et al, 1991). In
keeping with these observations, one group has shown that the
major effect of EGF in PC3 cells is to promote invasion, rather than
to stimulate cell proliferation (Jarrard et al, 1994).
LNCaP cells express far fewer EGFRs than the two androgen-
unresponsive DU145 and PC3 cell lines (Wilding et al, 1989).
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Figure 10 Proposed model for differential sorting and transport of EGFR by TGF-a and EGF in prostate cancer cells. The active ligand–receptor complex
(TGF-a–EGFR or EGF–EGFR) is internalized to clathrin coated pits and then to endosomes. For TGF-a, the receptor–ligand complex undergoes dissociation of
the ligand and the inactive EGFR is recycled back to plasma membrane. For EGF, the ligand–receptor complex undergoes transcytosis and lysosomal
degradation. Dephosphorylation and inactivation of the EGFR tyrosine kinase occurs in the endosomal compartments. The sorting protein nexin (SNX1) may
play a role to facilitate targetting of the EGF–EGFR complex to lysosomesHowever, the regulation of EGFR expression and proliferative
responses to EGF and TGF-a that we observed in LNCaP and
DU145 cells were similar. Thus, in androgen-responsive prostate
cancer cells, the EGFR pathway may make a significant contribu-
tion to cellular proliferation. As a consequence, blocking the
EGFR pathway earlier in the treatment of prostate cancer when
tumours are androgen-sensitive may provide a therapeutic advan-
tage. Studies to address the role of dual anti-androgen and anti-
EGFR treatment strategies to reduce prostate cancer cell growth
will be required to address this issue.
In summary, these data demonstrate the complexity of the
regulation of EGFR expression by TGF-a and EGF in prostate
cancer cells. EGFR transcription, mRNA decay, protein synthesis
and protein decay are regulated differentially by EGF and TGF-a
and in a cell-specific manner. These studies provide novel insight
into differences of action of each ligand at the molecular level. We
have defined the molecular mechanisms which indicate a preferred
role for TGF-a in the maintenance of an autocrine loop for pro-
liferative growth. In this context, a change in autocrine synthesis
from EGF to TGF-a during progression from hormone-responsive
to advanced prostate carcinomas would result in a net increase in
EGFR protein expression and could confer a significant growth
advantage to the cells. Furthermore, these data emphasize the need
to consider blocking the EGFR proliferative pathway earlier in the
androgen-responsive phase of human prostate cancer in order to
improve therapeutic outcomes.
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